Histogenics Corporation

📍 Waltham, United States🗓 Founded 2000👥 10 employees💰 Last funded Nov 2013
Biotechnology Research
LinkedIn
Histogenics was acquired by Ocugen, (Nasdaq: OCGN) on September 27, 2019. Histogenics (Nasdaq: HSGX) is a leader in personalized restorative cell therapies (RCT) for active living. Our first investigational product candidate, NeoCart® is a proprietary RCT that rebuilds a patient’s own knee cartilage, treating pain at the source and potentially preventing progression to osteoarthritis (OA). Read our community guidelines: https://goo.gl/Qtusgh
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2000
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Histogenics Corporation?
Histogenics Corporation has 1 investors on record on gritt.io.
When did Histogenics Corporation last raise funding?
The most recent investment in Histogenics Corporation recorded on gritt.io was in November 2013.
When was Histogenics Corporation founded?
Histogenics Corporation was founded in 2000.
What industry is Histogenics Corporation in?
Histogenics Corporation operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Histogenics Corporation based?
Histogenics Corporation is headquartered in Waltham, United States.